134 related articles for article (PubMed ID: 38411168)
1. Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.
Yusuf J; Prakash G; Safal S; Mehta V; Mukhopadhyay S
Coron Artery Dis; 2024 May; 35(3):186-192. PubMed ID: 38411168
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
[TBL] [Abstract][Full Text] [Related]
3. Effect of Nicorandil Administration on Preventing Contrast-Induced Nephropathy: A Meta-Analysis.
Zhan B; Huang X; Jiang L; Bao H; Cheng X
Angiology; 2018 Aug; 69(7):568-573. PubMed ID: 28950711
[TBL] [Abstract][Full Text] [Related]
4. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Oral Nicorandil to Prevent Contrast-Induced Nephropathy in Patients with Chronic Renal Dysfunction Undergoing an Elective Coronary Procedure.
Fan Z; Li Y; Ji H; Jian X
Kidney Blood Press Res; 2019; 44(6):1372-1382. PubMed ID: 31639790
[TBL] [Abstract][Full Text] [Related]
6. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study).
Ko YG; Lee BK; Kang WC; Moon JY; Cho YH; Choi SH; Hong MK; Jang Y; Kim JY; Min PK; Kwon HM;
Yonsei Med J; 2013 Jul; 54(4):957-64. PubMed ID: 23709432
[TBL] [Abstract][Full Text] [Related]
7. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of nicorandil on the prevention of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention.
Zhang X; Yang S; Zhang P; Fu N
Coron Artery Dis; 2020 May; 31(3):284-288. PubMed ID: 31658134
[TBL] [Abstract][Full Text] [Related]
9. Nicorandil Reduces the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography/Intervention - Systematic Review and Meta-Analysis of Randomized Controlled Trials Including GRADE Qualification.
Pranata R; Vania R; Alkatiri AA; Firman D; Lukito AA
Cardiovasc Revasc Med; 2020 Sep; 21(9):1121-1127. PubMed ID: 31959562
[TBL] [Abstract][Full Text] [Related]
10. Preventive Effects of Nicorandil Against Contrast-Induced Nephropathy in Patients With Moderate Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
Zhang P; Li WY; Yang SC; Fu NK; Liu XG; Zhang X; Cong HL; Lin WH; Tian FS; Lu CZ; Zhang J
Angiology; 2020 Feb; 71(2):183-188. PubMed ID: 30987432
[TBL] [Abstract][Full Text] [Related]
11. Comparison of double-dose vs. usual dose of nicorandil for the prevention of contrast-induced nephropathy after cardiac catheterization.
Zeng Z; Fu X; Zhang X; Fu N
Int Urol Nephrol; 2019 Nov; 51(11):1999-2004. PubMed ID: 31385178
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Nicorandil in Preventing Contrast-Induced Nephropathy after Elective Percutaneous Coronary Intervention: A Pooled Analysis of 1229 Patients.
Yi B; Mo S; Jiang Y; Yi D; Luo J; Chen X; Rong J
J Interv Cardiol; 2020; 2020():4527816. PubMed ID: 32982608
[TBL] [Abstract][Full Text] [Related]
13. Oral Nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial.
Abdollahi Moghaddam A; Baradaran Rahimi V; Morovatdar N; Rezaee R; Babalhekam SA
Int Urol Nephrol; 2023 Sep; 55(9):2327-2334. PubMed ID: 36881267
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial.
Marashizadeh A; Sanati HR; Sadeghipour P; Peighambari MM; Moosavi J; Shafe O; Firouzi A; Zahedmehr A; Maadani M; Shakerian F; Kiani R; Mohebbi B; Alemzadeh-Ansari MJ; Tahvili R; Naghavi B
Int Urol Nephrol; 2019 Oct; 51(10):1815-1822. PubMed ID: 31332700
[TBL] [Abstract][Full Text] [Related]
15. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
16. Remote ischemic preconditioning reduces the incidence of contrast-induced nephropathy in patients undergoing coronary angiography/intervention: Systematic review and meta-analysis of randomized controlled trials.
Pranata R; Tondas AE; Vania R; Toruan MPL; Lukito AA; Siswanto BB
Catheter Cardiovasc Interv; 2020 Nov; 96(6):1200-1212. PubMed ID: 31912996
[TBL] [Abstract][Full Text] [Related]
17. Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.
Barbieri L; Verdoia M; Suryapranata H; De Luca G;
Int J Cardiol; 2019 Jan; 275():48-52. PubMed ID: 30274753
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of brain natriuretic peptide
Mei Z; Luo S; Chen P; Zhang Q; Zhou L; Zhu C; Zhu H; Jin L
PeerJ; 2022; 10():e12975. PubMed ID: 35228908
[TBL] [Abstract][Full Text] [Related]
20. Aggressive hydraTion in patients with ST-Elevation Myocardial infarction undergoing Primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT): Study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for REduction of contraSt-induCed nephropathy followINg carDiac catheterization) trial.
Liu Y; Chen JY; Huo Y; Ge JB; Xian Y; Duan CY; Chen SQ; Jiang W; Chen PY; Tan N;
Am Heart J; 2016 Feb; 172():88-95. PubMed ID: 26856220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
